GlaxoSmithKline India stake @$940 mn

Nov 26 2012, 19:32 IST
Comments 0
GlaxoSmithKline Consumer Healthcare shares surge following news that its UK-based parent group plans to raise its stake in the unit. GlaxoSmithKline Consumer Healthcare shares surge following news that its UK-based parent group plans to raise its stake in the unit.
SummaryGSK plans to raise stake in Indian arm by up to 31.8 per cent for for Rs 5,220 cr.

Highlights:

* GlaxoSmithKline plans to raise stake in Indian arm by up to 31.8 pct

* Open offer at 3,900 rupees per share

* GSK Consumer Healthcare shares hit record high

GlaxoSmithKline Plc plans to buy up to an additional 31.8 percent stake in its Indian consumer products arm for about $940 million, as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health footprint.

GlaxoSmithKline plans to raise its stake in GlaxoSmithKline Consumer Healthcare Ltd to 75 percent from 43.2 percent, paying 3,900 rupees ($70.16) per share through an open offer, it said in a statement.

The price represents a premium of 28 percent to the stock's Friday close.

The news sent shares of GSK Consumer Healthcare to a record high. The shares were locked at 3,659.20 rupees, up 20 percent, their maximum daily trading limit, while the Mumbai market was up 0.23 percent, by 0600 GMT.

This transaction represents a further step in GSK's strategy to invest in the world's fastest growing markets, David Redfern, chief strategy officer at GlaxoSmithKline, said in the statement.

The company, however, has no current plans to launch an open offer for its Indian drugs unit GlaxoSmithKline Pharmaceuticals Ltd, he added.

HORLICKS PLAN

Tough market conditions in Europe have hampered GSK's hopes for a return to sales growth this year, although the company's growing business in emerging markets and its large consumer healthcare operation are both doing well.

In India, for example, sales of the consumer unit's flagship Horlicks brand stood at 270 million pounds ($432 million) in the year that ended December 2011, contributing to nearly three-quarters of its total revenues.

A lot of the current business of Horlicks is in the south and the east of India. So there is still a great opportunity to increase the penetration to the north and the west, Redfern said in an interview, adding that the company intended to introduce new variants of the brand in the country.

GlaxoSmithKline does not plan to delist the unit.

Securities regulations in India require a minimum public shareholding of 25 percent for a company to maintain a public listing.

The offer period is expected to begin in January 2013.

($1 = 55.5850 Indian rupees) ($1 = 0.6246 British pounds)

Stocks More on GlaxoSmithKline

Company INFO More on GlaxoSmithKline

GSK makes open offer for 31.8% stake in GSKCH for Rs 5,220 cr

New Delhi: (PTI) UK-based Healthcare and drug major GlaxoSmithKline today said it

Single Page Format
Ads by Google
Reader´s Comments
| Post a Comment
Please Wait while comments are loading...